TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Limaye, Dnyanesh
A1  - Todi, Krishna
A1  - Shroff, Jay
A1  - Ramaswamy, Ashutosh
A1  - Kulkarni, Priyanka
A1  - Limaye, Vaidehi
A1  - Fortwengel, Gerhard
T1  - Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India
JF  - International Journal of Community Medicine and Public Health
N2  - Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India. 
Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. 
Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). 
Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness.
KW  - Antidiabetic
KW  - Cost-effectiveness
KW  - Diabetes mellitus
KW  - India
KW  - Diabetes mellitus Typ 2
KW  - Antidiabetikum
KW  - Indien
KW  - Effizienz
Y1  - 2017
UN  - https://nbn-resolving.org/urn:nbn:de:bsz:960-opus4-19049
U6  - https://doi.org/10.25968/opus-1904
DO  - https://doi.org/10.25968/opus-1904
VL  - 4
IS  - 9
SP  - 3180
EP  - 3185
ER  -